ANZCTR search results

Treatment effectiveness: This study will determine whether there is a difference between the number and type of circulating tumour cells in cancer patients before and after treatment. Who is it for? You may be eligible to join this study if you are aged 18-80 years, diagnosed with any cancer and have received treatment at least 3 weeks ago or will receive treatment within one week. Study details The study aims to establish the Circulating Tumour Cell (CTC) detection method using the ISET (Isolation by Size of Epithelial/Trophoblastic Tumour Cells) device (Rarecells, France) in conjunction with cancer therapies offered at National Institute of Integrative Medicine. There will be no changes to the participants’ cancer treatment plans. Participants will be required to provide a blood sample at the beginning of their treatment and 3 months after commencement of treatment. The blood will be processed using the ISET technology to determine the number and types of circulating tumour cells. Early detection screening: This component of the study aims to determine whether the ISET-ED screening blood test can be used for early detection of cancer. Who is it for? You may be eligible to join this part of the study if you are aged between 18-80 years and have a family history of cancer, or have been diagnosed with chronic disease, or are attending a health check. Study details: Participants in this part of the study will undergo a blood test at baseline and at 3 months. The ISET-ED (early detection screening) test has the potential to detect potentially malignant cells, and other illness causing rare cells.

The aim of this study is to determine whether telehealth is more cost effective, feasible and acceptable than in person psychological support for adolescents and young adults (AYAs) with cancer. Who is it for? You may be eligible to join this study if you are aged between 15 years and 25 years and have been newly diagnosed or have relapsed with cancer, for which you will undergo curative or palliative therapy at any paediatric or adult cancer centre in NSW or ACT. Study details Participants in this study will be randomly (by chance) allocated to one of two groups. Participants in one group will receive psychological support via telehealth, whilst participants in the other group will receive in person psychological support. The psychosocial evaluation will be carried out at baseline, 6 months, 12 months and 24 months. All participants will be asked to complete a number of questionnaires at these time points relating to treatment acceptability and satisfaction, anxiety and quality of life. This will enable us to work out how effective telehealth is in implementing psychosocial support among AYAs with cancer, while also assessing its use as an age-appropriate model of delivering support, taking into account developmental concerns around autonomy and independence. An additional aim is to demonstrate evidence supporting the validity of the AYA Psychosocial Assessment Screening Tool and Psychosocial Assessment. While the distress thermometer (DT) is widely used and has been validated in numerous adult cancer populations, participants under the age of 18 have been excluded. Thus, there isn’t currently a validated instrument for measuring distress amongst AYAs with cancer.

A phytochemical- and mineral-rich filtered sugarcane molasses concentrate (FMC), when added to carbohydrate-containing foods as a functional ingredient, lowers postprandial blood glucose and insulin responses. We hypothesized that this beneficial effect would also occur if FMC was administered as an oral supplement taken before a meal. This study measured the postprandial glucose and insulin responses elicited by different doses of FMC administered immediately prior to a standard breakfast to healthy subjects. Each subject was given three or five breakfast meals once, on different days. The composition of the meals was identical, except for the addition of either placebo syrup (Test Meal 1), or increasing doses of FMC (Test Meals 2-5).

To assess clinical outcomes of patients who received direct percutaneous endoscopic jejunostomy (DPEJ) for enteral feeding.

This study aims to investigate the efficacy of daily supplementation of a commercially available fermented milk product (Yakult) to increase gut microbial content. Specifically, it is hypothesized that ingestion of Yakult for 14 days will increase the concentration of intestinal Lactobacillus casei strain Shirota (LcS) in 25 young healthy adults (18 - 35 yr).

When a neonate requires intubating it needs to occur quickly. Successful intubation can be challenging in small infants. It entails visualization of the glottis followed by insertion of the endotracheal tube through the cords, in a timely manner with minimal compromise to the infant. The current method is to use a laryngoscope to allow direct vision of the vocal cords. Direct vision requires a line of sight along the laryngoscope blade with a light source to view the vocal cords. In the neonate achieving a good view can be a challenge. The videolaryngoscope enables an excellent view of the glottis and its use has been widely studied in adults and paediatric surgical patients. Although many neonatal intensive care units (NICU’s) have integrated the use of this tool into standard care, there is limited evidence for its’ use in neonates. Intubation is a specialised skill and takes time to learn. The more attempts and longer it takes to intubate can potentially impact on an infant due to hypoxia or local trauma. We need to expand our knowledge of the safety of this instrument in acute neonatal care, value in the usefulness of the tool and determine its potential for teaching. If the videolaryngoscope is superior to the standard method, then its use may become even more widely implemented.

The aim of this project is to investigate the effects of a 6 month lifestyle intervention, based on a diet and exercise program, on cognitive function, mood general health and well-being. The intervention will be conducted in those aged 60-90 years who live independently in age care accommodation. We have published data showing that it is possible to improve mood and cognitive parameters in younger individuals with as little as 10 days adherence to a Mediterranean diet. The six month intervention period represents maintenance over a longer period of time important for longer term adoption of a change of lifestyle.

The study is to investigate the safety and tolerability of propagermanium on patients exhibiting proteinuria and who are already taking standard irbesartan therapy.

We are undertaking a randomised, placebo-controlled trial of a twice daily protein preload (20 g whey preload mixed with 5 g guar), taken before breakfast and dinner, to test the hypothesis that glycated haemoglobin (HbA1c) will be reduced by at least 0.5% compared to baseline at 12 weeks, in patients with type 2 diabetes who have relatively good glycaemic control (HbA1c less than or equal to 7.9%) on diet or metformin therapy alone. We will also test the secondary hypothesis that the whey preload (i) will induce slowing of gastric emptying, stimulation of incretin hormones and insulin, and reduce appetite and glycaemia after a standardised meal, and that these effects are sustained over 12 weeks; (ii) will induce greater reduction in HbA1c in subjects with more rapid gastric emptying at baseline; (iii) is not associated with weight gain, due to “compensation” for the increased protein load; and (iv) will reduce HbA1c independently of changes in insulin resistance, weight, or body composition.

The purpose of this study is to investigate the effects of Laughter Yoga on patients with kidney disease undergoing haemodialysis. The hypothesis was that laughter would have an affect on psychological variables such as happiness.